OAM Commences $8 Million Investigation Into Alternative Therapies

Alternative Therapies Author: Joy McIntyre The National Institutes of Health's Office of Alternative Medicine (OAM) has begun what promises to be a long and controversial process of investigating a vast array of alternative treatments-including therapies such as Chinese herbs, binaural feedback, massage, and mind-body techniques-for efficacy against a wide range of health threats. Nearly $8 million in funds previously earmarked by Congress will go out over three years to eight research center

Written byJoy Mcintyre
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

Alternative Therapies Author: Joy McIntyre

The National Institutes of Health's Office of Alternative Medicine (OAM) has begun what promises to be a long and controversial process of investigating a vast array of alternative treatments-including therapies such as Chinese herbs, binaural feedback, massage, and mind-body techniques-for efficacy against a wide range of health threats.

Nearly $8 million in funds previously earmarked by Congress will go out over three years to eight research centers throughout the United States specializing in such treatment areas as pain; stroke and neurological conditions; women's ailments, from pregnancy to menopause; cancer; lower back pain; coronary problems; addictions; HIV and AIDS; asthma, allergy, and immunology; and aging. Similar funding of slightly more than $900,000 each for two additional centers was dispersed last year.

The research supported by the awards, if confirming data from clinical trials are collected, may acknowledge some alternative techniques as useful, perhaps integrating them into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies